You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The precision medicine company also is accelerating its push into diabetes, depression, and cardiology after getting its solid-tumor test turnaround down to 9 days.
Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology.
A high genetic risk score was associated with increased risk of developing type 2 diabetes in both a US and a Danish cohort of women with gestational diabetes.
In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.
A prospective metagenomic sequencing study searched for viral changes in children who developed islet autoimmunity or type 1 diabetes, revealing coxsackievirus ties to autoimmunity.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
Researchers linked 16 genetic loci to diabetic kidney disease, including a common missense mutation in the COL4A3 gene that appears to be protective.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.
A Mendelian randomization analysis found visceral fat to be linked to cardiometabolic disease risk, especially type 2 diabetes risk in women.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.